These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28194852)

  • 41. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score.
    Dakin H; Gray A; Murray D
    Qual Life Res; 2013 Apr; 22(3):683-94. PubMed ID: 22555470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health-related quality of life measured using the EQ-5D-3L: iranian population norms.
    Mousavi A; Sari AA; Daastari F; Daroudi R
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):643-651. PubMed ID: 38450671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis.
    Martín-Fernández J; Morey-Montalvo M; Tomás-García N; Martín-Ramos E; Muñoz-García JC; Polentinos-Castro E; Rodríguez-Martínez G; Arenaza JC; García-Pérez L; Magdalena-Armas L; Bilbao A
    Health Qual Life Outcomes; 2020 Jun; 18(1):184. PubMed ID: 32539838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mapping of Family Reported Outcome Measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values.
    Shah R; Salek MS; Finlay AY; Kay R; Nixon SJ; Otwombe K; Ali FM; Ingram JR
    Qual Life Res; 2024 Apr; 33(4):1107-1119. PubMed ID: 38402530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
    Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
    Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mapping the Minnesota living with heart failure questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure.
    Kularatna S; Senanayake S; Chen G; Parsonage W
    Health Qual Life Outcomes; 2020 Apr; 18(1):115. PubMed ID: 32349782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
    Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
    Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
    Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index.
    Hanmer J; Cherepanov D; Palta M; Kaplan RM; Feeny D; Fryback DG
    Med Decis Making; 2016 Feb; 36(2):264-74. PubMed ID: 26314728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey.
    Jankowska A; Młyńczak K; Golicki D
    Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).
    Badia X; Roset M; Valassi E; Franz H; Forsythe A; Webb SM
    Qual Life Res; 2013 Dec; 22(10):2941-50. PubMed ID: 23539468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D.
    Riis PT; Vinding GR; Ring HC; Jemec GB
    Acta Derm Venereol; 2016 Feb; 96(2):222-6. PubMed ID: 25940640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
    Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
    MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
    [No Abstract]   [Full Text] [Related]  

  • 55. Mapping utility scores from a disease-specific quality-of-life measure in bariatric surgery patients.
    Sauerland S; Weiner S; Dolezalova K; Angrisani L; Noguera CM; García-Caballero M; Rupprecht F; Immenroth M
    Value Health; 2009; 12(2):364-70. PubMed ID: 20667063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.
    Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J
    Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mapping the Lequesne Functional Index Into the EQ-5D-5L Utility Index in Patients With Knee Osteoarthritis.
    Dardenne N; Donneau AF; Bruyère O
    Value Health; 2024 Oct; 27(10):1400-1407. PubMed ID: 38977193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
    Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
    BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mapping between the Roland Morris Questionnaire and generic preference-based measures.
    Khan KA; Madan J; Petrou S; Lamb SE
    Value Health; 2014 Sep; 17(6):686-95. PubMed ID: 25236992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities.
    Blome C; Beikert FC; Rustenbach SJ; Augustin M
    Arch Dermatol Res; 2013 Apr; 305(3):197-204. PubMed ID: 23266843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.